Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Interferon therapy in malignant melanoma]

E M Kokoschka¹, M Micksche

¹Dermatologischen Universitätsklinik Wien.

Wiener Medizinische Wochenschrift (1946)

|January 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).

Current cancer drug targets·2009

Same author

Vaults and the major vault protein: novel roles in signal pathway regulation and immunity.

Cellular and molecular life sciences : CMLS·2008

Same author

New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis.

British journal of cancer·2008

Same author

FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.

Oncogene·2008

Same author

Probiotic, as well as conventional yogurt, can enhance the stimulated production of proinflammatory cytokines.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2007

Same author

Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

Biochemical pharmacology·2007

Malignant melanoma incidence is rising, with limited treatment options for high-risk cases. Interferon-alpha therapy shows promise in improving outcomes for melanoma patients.

Area of Science:

Oncology
Dermatology
Immunology

Context:

Rising incidence of malignant melanoma in Caucasian populations.
Increased mortality and morbidity rates associated with melanoma.
Limitations in established therapy regimens for high-risk stage I/II and metastatic melanoma.

Purpose:

To evaluate the efficacy of Interferon-alpha as an adjuvant therapy for melanoma.
To explore the potential of combining chemotherapy with Interferon-alpha for advanced melanoma.

Summary:

Interferon-alpha therapy has demonstrated improvements in relapse-free intervals and survival rates.
Combination therapy involving chemotherapy and Interferon-alpha resulted in a significant increase in treatment success risk (up to 20%).

Related Experiment Videos

Impact:

Highlights the potential of Interferon-alpha in melanoma treatment, particularly for high-risk and advanced stages.
Suggests a promising therapeutic strategy for improving patient survival and reducing relapse rates in malignant melanoma.